Skip to main content

Table 4 Parasite reduction ratios in the various groups

From: A randomized trial of artesunate-amodiaquine versus artemether-lumefantrine in Ghanaian paediatric sickle cell and non-sickle cell disease patients with acute uncomplicated malaria

Group Day of treatment Parasite density (geometric mean) PRR Time to 50 % parasite density (days) Time to 90 % parasite density (days)
SCD Day 0 1197 -   -
Day 1 788 1.52 2 5
Day 2 599 1.99   
Day 3 226 5.28   
HbAA Day 0 11,774 -   
Day 1 2,811 4.18 0.6 1.6
Day 2 118 99.23   
Day 3 32 367.95   
SCD-AA Day 0 1,012 -   
Day 1 684 1.47 2.7 3
Day 2 2,135 0.47   
Day 3 64 15.81   
SCD-AL Day 0 1,408 -   
Day 1 869 1.62 1.25 7
Day 2 228 6.15   
Day 3 2840 0.49   
  1. SCD = sickle cell disease, HbAA = non-SCD, SCD-AA = SCD subjects treated with artesunate-amodiaquine, SCD-AL = SCD subjects treated with artemether-lumefantrine.